CONFERENCEProject title: Orchestrating Multi-Omic Nanomedicine Insights with AI and Spatial Biology–Driven Innovation and Training for Hard-to-Treat Cancers (OMNIA)
Grant agreement ID: 101299913; https://cordis.europa.eu/project/id/101299913
Implementation time: 01.09.2026-31.08.2030
Project coordinator: Ankara University, Turkey (Ankara Üniversitesi)
Total project funding: 1 803 600 EUR
University of Latvia funding: 245 490 EUR
Research coordinator in Latvia: Dr. Maksym Pogorielov (Advanced Biomaterials and Biophysics Laboratory)
Administrative manager in Latvia: Inga Šīrante, FST project manager
Project Consortium:
Coordinator - Ankara Üniversitesi, Turkey
Beneficiaries (13)
- The University of Birmingham, United Kingdom
- Latvijas Universitāte, Latvia
- Università degli studi Padova, Italy
- Universidade de Coimbra, Portugal
- Uniwersytet im. Adama Mickiewicza w Poznaniu, Poland
- Turun yliopisto, Finland
- CSD Health Care, Ukraine
- Bluepharma Indústria Farmacêutica S.A., Portugal
- YOURSCIENCEBE SRL, Belgium
- Центр Материаловедения - Materials Research Centre, Ukraine
- Centre de lutte contre le cancer, le Centre Léon Bérard, France
- Institut Català de Nanociència i Nanotecnologia, Spain
- Università degli Studi di Sassari, Italy
Other Partners (9)
- Drexel University, United States
- University of Miami, United States
- University of Manitoba, Canada
- Khalifa University of Science and Technology, United Arab Emirates
- Augusta University Research Institute Inc., United States
- Pusan National University, South Corea
- L'Institut national de la santé et de la recherche médicale, France
- Centre national de la recherche scientifique, France
- Lyon 1 Université Claude Bernard, France
Project Objective: OMNIA is a European-led, globally connected research and training programme redefining how nanotherapeutics are designed and translated for hard-to-treat cancers. By integrating spatial multi-omics, advanced tumor models, and interpretable AI, OMNIA uncovers how nanoparticles interact with the tumor microenvironment—turning complex molecular data into actionable design rules for safer, more effective treatments.
Through a harmonized nanoparticle platform, standardized SOPs, and FAIR-compliant data pipelines, OMNIA transforms fragmented nanomedicine studies into a reproducible, data-driven field. Its consortium of leading academic, clinical, and industrial partners from Europe, North America, and Asia bridges expertise in materials science, oncology, and AI to deliver open spatial atlases, validated analysis tools, and regulatory-ready templates.
At its core, OMNIA is also a training ecosystem. Over 80 researchers will engage in structured, cross-sector secondments—“capsule curricula” that combine hands-on experimentation, AI analysis, and translational science. This approach cultivates a new generation of scientists fluent in materials–biology–AI integration and capable of driving Europe’s next wave of cancer nanomedicine.
Organized into five interconnected work packages spanning nanoparticle design, characterization, spatial biology, AI, and ethics, OMNIA combines scientific excellence, industrial innovation, and mobility-driven collaboration—laying the foundation for a sustainable, spatially informed, AI-enabled future in nanomedicine.